Emergent Product Development Gaithersburg Inc. Contracts in Maryland
Federal contract operations by Emergent Product Development Gaithersburg Inc. performed in Maryland (MD)
Overview
Total Contract Value: $2,604,091,480
Contract Count: 11
Average Contract Size: $236.7M
Sole Source Rate: 0%
Small Business Rate: 0%
Awarding Agencies
- Department of Health and Human Services — $2.6B (11 contracts)
Spending by Sector
- R&D: $1.8B (10 contracts)
- Healthcare: $804.9M (1 contracts)
Contracts
- IGF::OT::IGF — $1.4B
- ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM) — $804.9M
- MEDICAL COUNTERMEASURES (MCM) THAT CAN BE DEPLOYED IN THE EVENT OF A FILOVIRUS OUTBREAK ARE A CRUCIAL COMPONENT TO THE UNITED STATES GOVERNMENT?S (USG?S) OUTBREAK RESPONSE PLAN. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) IS SEEKIN — $118.6M
- TAS::75 0140::TAS ADVANCED DEVELOPMENT OF RECOMBINANT PROTECTIVE ANTIGENT (RPA) ANTHRAX VACCINE CAN 1990087 — $93.0M
- IGF::OT::IGF FOR OTHER FUNCTIONSTHIS CONTRACT IS FOR THE ADVANCED DEVELOPMENT OF NUTHRAX (ANTHRAX VACCINE ABSORBED WITH CPG 7909) OR AV7909 — $43.8M
- TAS::75 0885::TAS DEVELOPMENT OF TECHNOLOGIES TO FACILITATE THE USE OF, AND RESPONSE TO, BIODEFENSE VACCINES — $38.0M
- IGF::OT::IGF - ADVANCING STABILIZED ISOAMYL NITRITE FOR INTRANASAL TREATMENT OF CYANIDE EXPOSURE — $33.0M
- IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS — $30.2M
- BIOMEDICAL (ADVANCED) — $26.7M
- NEW AWARD UNDER BAA NIH-NIAID-DMID-08-20. THIS IS ONE OF FOUR AWARDS UNDER THIS BAA. — $18.1M
- BIOMEDICAL (BASIC) — $12.2M
Frequently Asked Questions
How many contracts does Emergent Product Development Gaithersburg Inc. have in Maryland?
Emergent Product Development Gaithersburg Inc. has 11 contracts performed in Maryland worth a combined $2.6B.
What is the average contract size for Emergent Product Development Gaithersburg Inc. in Maryland?
The average contract size is $236.7M.